Eribulin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Eribulin: From Liposarcoma to Autosomal Recessive Familial Mediterranean Fever
One-Sentence Summary
Eribulin is a cytotoxic chemotherapy originally used to treat liposarcoma. The TxGNN model predicts it may be effective for autosomal recessive familial Mediterranean fever (FMF), with a very high score. However, no clinical trials and no publications currently support this prediction, so it rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Liposarcoma |
| Predicted New Indication | Autosomal recessive familial Mediterranean fever |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Eribulin inhibits microtubule dynamics, which blocks cell division. This makes it useful against rapidly proliferating tumours such as soft tissue sarcoma. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description is based on the drug's known pharmacology.
FMF is a hereditary autoinflammatory disease. It is driven by dysregulation of the MEFV/pyrin inflammasome, not by uncontrolled cell growth. The only loose conceptual link is that colchicine, the standard FMF therapy, also acts on microtubules. That is a weak parallel. A cytotoxic chemotherapy is not a plausible treatment for a chronic, non-malignant inflammatory condition. The high TxGNN score (0.998) is most likely an artifact of the knowledge graph structure and not a real biological signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13917P | Halaven Solution for Injection 0.5mg/mL | Injection, solution | Not stated in the registration record |
The product is a valid single-ingredient registration.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (microtubule dynamics inhibitor) |
| Myelosuppression Risk | High (neutropenia and thrombocytopenia are listed among the drug's contraindicated conditions in the knowledge graph) |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | CBC with differential, liver and renal function, electrolytes (potassium, magnesium), ECG for QT interval, neurological assessment for peripheral neuropathy |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Please also refer to the package insert warnings and precautions.
Safety Considerations
- Disease-level contraindication signals (from the knowledge graph, not label text): long QT syndrome (including familial), thrombocytopenia, neutropenia, agranulocytosis, potassium deficiency, peripheral nervous system disease and peripheral neuropathy, and constipation disorder.
- Drug Interactions: 100 interactions were identified in total. The two rated Major are:
- Dolasetron
- Cisapride
Both are likely related to QT prolongation. Many Moderate interactions were also found, including:
- Antiemetics: ondansetron, palonosetron
- Antibiotics: clarithromycin, levofloxacin, metronidazole, tinidazole
- Statins: simvastatin, rosuvastatin
- Laxatives and bowel-preparation agents: bisacodyl, lactulose, polyethylene glycol
- Others: famotidine, loperamide
For full warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. There are no trials or publications, and the biological rationale is weak. FMF is a non-malignant inflammatory disease, and eribulin is a toxic cytotoxic drug with significant myelosuppression, neuropathy and QT risks. The risk-benefit balance is unfavourable, and well-established, safer FMF therapies exist.
To proceed, the following is needed:
- Detailed mechanism of action data and a credible mechanistic link to pyrin/inflammasome biology
- Preclinical evidence in an FMF-relevant model
- Package insert warnings and contraindications from the Singapore regulator
- Approved indication text for the Singapore registration
Note on other candidates: Among the other predicted indications, fibroblastic neoplasm (rank 8) has the strongest support. It has a completed Phase 2 trial in advanced solitary fibrous tumour (NCT03840772, n=16, no results in the data compiled), plus supporting preclinical literature. This direction is a more sensible research question than FMF and may deserve priority review.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.